Marginal zone B-cell lymphoma
|Marginal zone B-cell lymphoma|
|Marginal zone lymphoma located in the kidney tissue.|
Marginal Zone B-cell Non-Hodgkins Lymphoma (NHL) is a type of lymphoma that affects B-cells in the marginal zones of various areas. Marginal zone lymphomas are slow growing and make up about 12% of all B-cell NHL. The median age for diagnosis is 65 years old and is primarily present in the stomach, intestines, salivary glands, lung, thyroid gland, lacrimal gland, conjunctiva, bladder, kidney, skin, soft tissue, thymus gland, and breast. The three types of marginal zone lymphomas include extranodal marginal zone lymphoma (MALT), nodal marginal zone lymphoma, and splenic marginal zone lymphoma. Marginal zone lymphomas are those that develop in the marginal zone or edge of the lymphoid tissue where B-cells are located. All marginal zone lymphomas are low-grade B-cell NHL. Nodal MZL makes up less than 2 in 100 NHL cases, MALT lymphoma makes up 1 in 13 NHL cases, and splenic marginal zone NHL makes up less than 2 in 100 NHL cases. Symptoms tend to vary from each individual patient and are often not enough to make an immediate diagnosis, as this cancer may have similar symptoms to other diseases. Prognosis and treatment are dependent on the location of the cancer and the stage of diagnosis.
- 1 Symptoms
- 2 Mechanism/Pathophysiology
- 3 Diagnosis
- 4 Risk factors
- 5 Treatment and prognosis
- 6 Recent research
- 7 References
- 8 External links
Nodal Marginal Zone B-cell NHL
Individuals with this type of cancer experience almost no symptoms at all.
- Painless lymphadenopathy
- Weight loss
- Night sweat
Extranodal Marginal Zone B-cell NHL
- Abdominal discomfort
- Nausea and vomiting
- Weight loss
- Mass in the abdomen (rare)
Most individuals with non-gastric MALT have no symptoms
- Symptoms depend on where the cancer originates:
Marginal cell lymphomas are likely derived from cells located in the nodal zone or splenic marginal zone. The cells are derived from B memory cells in the post germinal area and IgM+ or IgD-. It is common to find high LDH levels and serum b2-microglobulin in these individuals. Marginal zone lymphomas generally lack markers in order to come up with an overall diagnosis. CD20 antibodies were found to be present in 100% of the cases, CD43 antibodies were present in 24% of the cases, BCL2 antibodies were present in 43% of the cases, follicular colonization was present in 27% of the cases, CD23 antibodies were present in only 5% of the cases, increased polyclonal plasma cells were present in 8% on the cases, monoclonal plasma cells were present in 31% of the cases, kappa antibodies were present in 44% of the cases, and lambda antibodies were present in 56% of the cases.
Nodal Marginal Zone B-cell NHL
Nodal MZL is generally diagnosed by taking a biopsy of the affected tissue. This subtype is difficult to diagnose due to its similarity to other types of lymphoma. In order to determine the correct type of lymphoma and stage it accurately, the physician will also need to do a physical exam, blood tests to determine blood cell counts, a CT scan, and/or a PET scan. A PET scan is the most important in planning a course of treatment. A bone marrow biopsy and aspiration test may also be ordered to test for bone marrow involvement, which is found in 30-50% of cases.
In order to diagnose MALT, a biopsy is needed from the affected tissue. If the abnormal tissue is suspected to be in the stomach or bowel, an endoscopy is done in order to get the biopsy. This requires either a gastroscopy or colonoscopy. If the lymphoma is thought to have spread to other areas in this region, an ultrasound scan is often done at the same time. If the abnormal tissue is thought to be in the lungs, a bronchoscopy is ordered.
In order to determine the correct type of lymphoma and stage it accurately, the physician will also need to do a physical exam, blood tests to determine blood cell counts, a CT scan, an MRI and/or a PET scan. A PET scan is the most important in planning a course of treatment.
A bone marrow biopsy may be ordered to test for lymph node involvement. If the lymphoma is in the stomach, the physician will test for H. pylori infection through a stool sample. This infection would be necessary to treat in conjunction to treating the cancer.
Splenic Marginal Zone B-cell NHL
Splenic MZL is difficult to diagnose and can look similar to other types of lymphoma. Tests include a physical examination, blood tests to determine overall health and detect infections (ex. hepatitis C), a bone marrow biopsy, CT scan, and a PET scan. Sometimes a splenectomy is necessary during the diagnosis process in order to determine the exact type of lymphoma. If the spleen is removed, you will be at a larger risk of infection.
Factors that may increase an individuals chance of developing nodal MZL are being over the age of 60 and having been infected with hepatitis C virus. Factors that may increase an individuals chance of developing MALT lymphoma include being over the age of 50, having an autoimmune condition (rheumatoid arthritis, Hashimoto's thyroiditis), and long lasting chronic inflammation due to infection (H.pylori, Sjogren syndrome, Chlamydia infection, Borrelia infection, Campylobacter jejuni infection). Factors that increase an individuals risk of developing splenic MZL include the hepatitis C virus, Epstein-Barr virus, malaria, Sjogren syndrome, and lupus.
In order to reduce the chances of developing MZL, an individual can decrease their exposure to the possible risk factors.
Treatment and prognosis
Nodal Marginal Zone B-cell Lymphoma
Treatment is dependent if the lymphoma is causing issues in regards to the overall health of the individual. Since this a slow moving cancer, many patients start treatment when the symptoms appear. If the individual tests positive for hepatitis C, then anti-viral treatment is suggested since it will often get rid of the lymphoma as well. If further treatment is required the options include chemotherapy, monoclonal antibodies, and/or radiation. Radiation therapy is used for stage I and II nodal marginal zone NHL. Clinical trials show success in treatment when using drugs such as bendamustine and lenalidomida in combination with rituximab.
The primary treatment for MALT is antibiotics to treat an underlying infection such as H.pylori. H.pylori is directly related to the development of this lymphoma. Since most patients respond well to this treatment, then no further treatment is needed. If the lymphoma is not linked to an infection, then radiotherapy and chemotherapy are needed. If the disease is more advanced, then immunoradiotherapy with chemotherapy will be needed. Among the common first-line treatments are bendamustine plus rituximab and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). Recently, antibiotic therapy such as doxycycline has been shown to be effective in marginal zone lymphoma that affects the area around the eye ("ocular adnexal marginal zone lymphoma").
Treatment is often dependent on if the lymphoma is causing issues in regards to the overall health of the individual. Since this a slow moving cancer, many patients start treatment when the symptoms appear. If the individual tests positive for hepatitis C, then anti-viral treatment is suggested since it will often get rid of the lymphoma as well. A splenectomy is generally taken as the initial form of treatment and used to confirm the diagnosis. Further treatment of this cancer is generally not needed until years later and may include chemotherapy, antibody therapy, and/or radiotherapy if the spleen was not initially removed.
Diet and activity
Generally individuals with MZL can follow a normal diet. Neutropenic individuals are instructed to avoid raw fruits and vegetables. Individuals with thrombocytopenia or neutropenia should use toothette swabs to clean teeth, avoid shaving with razors, avoid intramuscular injections, and should instruct all individuals to wash their hands if they are near by.
An individuals prognosis can be based on the Ann Arbor Staging System. If an individual is diagnosed with Stage I marginal zone B-cell NHL, this indicates that there is involvement of a single lymph node region and/or involvement of a single extra-lymphatic organ. Stage II indicates that two or more lymph node regions on the same side of the diaphragm and/or involvement of an extra-lymphatic organ or site and one or more lymph node on the same side of the diaphragm. Stage III indicates involvement of lymph nodes on both sides of the diaphragm, splenic involvement, and extra lymphatic site involvement. Stage IV indicates involvement of more than one extra lymphatic organ or tissues without lymph node involvement. If symptoms such as fever, night sweats, and more than a 10% weight loss are experienced within the first six months, this is characterized by a "B" for present. If these symptoms are absent this is characterized by an "A" for absent. Extra-nodal sites are characterized as follows: marrow (M+), lungs (L+), liver (H+), pleura (P+), bone (O+), and skin and subcutaneous tissue (D+).
Nodal MZL not only develops at a very slow rate but often relapses in individuals. These individuals often survive for a long time with treatment at various points in their life to keep the cancer at bay. MALT lymphoma also develops at a slow rate and is usually treated successfully even when present in various areas of the body. Splenic MZL also develops at a slow rate but is usually incurable. Even though it is not generally cured, it can be managed for many years
It is important to note that the prognosis of individual cases varies and further information will be available through a physician.
Various new drugs such as B-cell receptor signaling blockers and ibritumomab tiuxetan (Zevlin) are being tested in clinical trials for MZL. These trials are important in determining dosages and safety of the drugs in study. As of January 19, 2017, the FDA approved the first ever targeted drug for MZL, ibrutinib. This drug works by inhibiting Bruton's tyrosine kinase (BKT), which is able to send signals to the nucleus for survival. In other words, it slows the growth of B-cells.
Even though a splenectomy is still seen as a first line of treatment for splenic marginal zone lymphoma, recent studies show that the drug Rituximab could also be successfully used as a first line of treatment. In patients with extra-nodal MALT, it was found that survival increases if the cancer was treated when found early and MALT found in the stomach had the lowest incidence rate of relapse. This indicates that localized therapies are very effective in the treatment of extra-nodal marginal zone lymphoma when found early in early stages.
- "Marginal Zone Lymphoma - Lymphoma Research Foundation". www.lymphoma.org. Retrieved 2017-11-06.
- "Nodal marginal zone lymphoma". Lymphoma Association. 2017-01-19. Retrieved 2017-11-07.
- "MALT lymphoma (including gastric MALT lymphoma)". Lymphoma Association. 2017-01-19. Retrieved 2017-11-07.
- "Splenic marginal zone lymphoma". Lymphoma Association. 2017-01-19. Retrieved 2017-11-07.
- "Marginal zone B cell lymphoma - General". www.pathologyoutlines.com. Retrieved 2017-12-11.
- "Marginal-zone B cell lymphoma". e-immunohistochemistry.info. Retrieved 2017-12-11.
- Salama, Mohamed E.; Lossos, Izidore S.; Warnke, Roger A.; Natkunam, Yasodha (July 2009). "IMMUNOARCHITECTURAL PATTERNS IN NODAL MARGINAL ZONE B-CELL LYMPHOMA: A STUDY OF 51 CASES". American journal of clinical pathology. 132 (1): 39–49. doi:10.1309/AJCPZQ1GXBBNG8OG. ISSN 0002-9173. PMC 2894708. PMID 19864232.
- "Lymphoblastic Lymphoma: Overview, Etiology and Pathophysiology, Epidemiology". 2017-01-06.
- "Non-Hodgkin's lymphoma Risk factors". Mayo Clinic. Retrieved 2017-11-06.
- "Lymphoma - Non-Hodgkin: Subtypes | Cancer.Net". Cancer.Net. 2012-06-25. Retrieved 2017-11-06.
- "Grading Staging Report - Splenic Marginal Zone B Cell Lymphoma - Surgical Pathology Criteria - Stanford University School of Medicine". surgpathcriteria.stanford.edu. Retrieved 2017-11-25.
- "Marginal Zone Lymphoma - Lymphoma Research Foundation". www.lymphoma.org. Retrieved 2017-12-10.
- "FDA Approves First-Ever Targeted Marginal Zone Lymphoma Treatment". New Developments in Lymphoma. 2017-01-19. Retrieved 2017-12-10.
- Kalpadakis, Christina; Pangalis, Gerassimos A.; Angelopoulou, Maria K.; Sachanas, Sotirios; Kontopidou, Flora N.; Yiakoumis, Xanthi; Kokoris, Stella I.; Dimitriadou, Evagelia M.; Dimopoulou, Maria N. (2013-02-01). "Treatment of Splenic Marginal Zone Lymphoma With Rituximab Monotherapy: Progress Report and Comparison With Splenectomy". The Oncologist. 18 (2): 190–197. doi:10.1634/theoncologist.2012-0251. ISSN 1083-7159. PMC 3579603. PMID 23345547.
- Teckie, S.; Qi, S.; Chelius, M.; Lovie, S.; Hsu, M.; Noy, A.; Portlock, C.; Yahalom, J. (2017-05-01). "Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma". Annals of Oncology. 28 (5): 1064–1069. doi:10.1093/annonc/mdx025. ISSN 0923-7534.